Rebecca A Smith, Samara Eisenberg, Aaron Turner-Pfifer, Jacqueline Le Grand, Sarah Pincus, Yousra Omer, Fei Wang, Bruce Pyenson
{"title":"我们即将找到治疗 1 型糖尿病的突破性疗法,但谁是 200 万美国患者?","authors":"Rebecca A Smith, Samara Eisenberg, Aaron Turner-Pfifer, Jacqueline Le Grand, Sarah Pincus, Yousra Omer, Fei Wang, Bruce Pyenson","doi":"10.1101/2024.07.24.24310877","DOIUrl":null,"url":null,"abstract":"Two million Americans have Type 2 Diabetes. Innovative treatments have standardized insulin delivery and improved outcomes for patients, but patients' access to such technologies depends on social determinants of health, including insurance coverage, proper diagnosis, and appropriate patient supports. Prior estimates of US prevalence, incidence, and patient characteristics have relied on data from select regions and younger ages and miss important determinants. By contrast, our research leveraged nationally representative administrative claims datasets to build a nuanced picture of the population with T1DM. Our work also supports future policy and research efforts with 2025, 2029, and 2035 projections of demographic and insurance coverage for people with T1DM.","PeriodicalId":501386,"journal":{"name":"medRxiv - Health Policy","volume":"68 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It?\",\"authors\":\"Rebecca A Smith, Samara Eisenberg, Aaron Turner-Pfifer, Jacqueline Le Grand, Sarah Pincus, Yousra Omer, Fei Wang, Bruce Pyenson\",\"doi\":\"10.1101/2024.07.24.24310877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Two million Americans have Type 2 Diabetes. Innovative treatments have standardized insulin delivery and improved outcomes for patients, but patients' access to such technologies depends on social determinants of health, including insurance coverage, proper diagnosis, and appropriate patient supports. Prior estimates of US prevalence, incidence, and patient characteristics have relied on data from select regions and younger ages and miss important determinants. By contrast, our research leveraged nationally representative administrative claims datasets to build a nuanced picture of the population with T1DM. Our work also supports future policy and research efforts with 2025, 2029, and 2035 projections of demographic and insurance coverage for people with T1DM.\",\"PeriodicalId\":501386,\"journal\":{\"name\":\"medRxiv - Health Policy\",\"volume\":\"68 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Health Policy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.07.24.24310877\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Health Policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.07.24.24310877","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It?
Two million Americans have Type 2 Diabetes. Innovative treatments have standardized insulin delivery and improved outcomes for patients, but patients' access to such technologies depends on social determinants of health, including insurance coverage, proper diagnosis, and appropriate patient supports. Prior estimates of US prevalence, incidence, and patient characteristics have relied on data from select regions and younger ages and miss important determinants. By contrast, our research leveraged nationally representative administrative claims datasets to build a nuanced picture of the population with T1DM. Our work also supports future policy and research efforts with 2025, 2029, and 2035 projections of demographic and insurance coverage for people with T1DM.